The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target
Open accessAbstract
Summary Bone marrow fibrosis (BMF) develops in various hematological and non-hematological conditions and is a central pathological feature of myelofibrosis. Effective cell-targeted therapeutics are needed, but the cellular origin of BMF remains elusive. Here, we show using genetic fate tracing in two murine models of BMF that Gli1+ mesenchymal stromal cells (MSCs) are recruited from the endosteal and perivascular niche to become fibrosis-driving myofibroblasts in the bone marrow. Genetic ablation of Gli1+ cells abolished BMF and rescued bone marrow failure. Pharmacological targeting of Gli proteins with GANT61 inhibited Gli1+ cell expansion and myofibroblast differentiation, and attenuated fibrosis severity. The same pathway is also active in human BMF and Gli1 expression in BMF significantly correlates with the severity of the disease. In addition, GANT61 treatment reduced the myofibroblastic phenotype of human MSCs isolated from patients with BMF, suggesting that targeting of Gli proteins could be a relevant therapeutic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
Méndez-Ferrer, S., Michurina, T. V., Ferraro, F., Mazloom, A. R., MacArthur, B. D., Lira, S. A., Scadden, D. T., Ma’ayan, A., Enikolopov, G. N., & Frenette, P. S. (2010) · Nature · doi:10.1038/nature09262 · Cited by 3,374
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Arteriolar niches maintain haematopoietic stem cell quiescence
Kunisaki, Y., Bruns, I., Scheiermann, C., Ahmed, J., Pinho, S., Zhang, D., Mizoguchi, T., Wei, Q., Lucas, D., Ito, K., et al. (2013) · Nature · doi:10.1038/nature12612 · Cited by 1,231
Perivascular Gli1+ Progenitors Are Key Contributors to Injury-Induced Organ Fibrosis
Kramann, R., Schneider, R. K., DiRocco, D. P., Machado, F., Fleig, S., Bondzie, P. A., Henderson, J. M., Ebert, B. L., & Humphreys, B. D. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.11.004 · Cited by 922 · cited 7×
“Perivascular and Endosteal Localization of Gli1 Cells in the BM Niche Having identified Gli1 as a faithful marker for fibrosis-driving MSCs in solid organs (Kramann et al., 2015b), we sought to characterize Gli1 cells in the BMnichemore thoroughly.”
InfluentialSelf-citationThe Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists
Lauth, M., Bergström, Å., Shimokawa, T., & Toftgård, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609699104 · Cited by 782
Väremo, L., Nielsen, J., & Nookaew, I. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt111 · Cited by 697
Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion
Bruns, I., Lucas, D., Pinho, S., Ahmed, J., Lambert, M. P., Kunisaki, Y., Scheiermann, C., Schiff, L., Poncz, M., Bergman, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3707 · Cited by 624
Schepers, K., Pietras, E. M., Reynaud, D., Flach, J., Binnewies, M., Garg, T., Wagers, A. J., Hsiao, E. C., & Passegué, E. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.009 · Cited by 614
on behalf of the COMFORT-II Investigators, Harrison, C. N., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M. M., Sun, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.148 · Cited by 519
Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis
van Bon, L., Affandi, A. J., Broen, J., Christmann, R. B., Marijnissen, R. J., Stawski, L., Farina, G. A., Stifano, G., Mathes, A. L., Cossu, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1114576 · Cited by 453
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
Schepers, K., Campbell, T. B., & Passegué, E. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.014 · Cited by 421
Wernig, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., Gozo, M., McDowell, E. P., Levine, R. L., Doukas, J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.009 · Cited by 390
El Agha, E., Moiseenko, A., Kheirollahi, V., De Langhe, S., Crnkovic, S., Kwapiszewska, G., Szibor, M., Kosanovic, D., Schwind, F., Schermuly, R. T., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2016.10.004 · Cited by 347
Kuter, D. J., Bain, B., Mufti, G., Bagg, A., & Hasserjian, R. P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06807.x · Cited by 304
Tzeng, Y.-S., Li, H., Kang, Y.-L., Chen, W.-C., Cheng, W.-C., & Lai, D.-M. (2011) · Blood · doi:10.1182/blood-2010-01-266833 · Cited by 280
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
Villeval, J.-L., Cohen-Solal, K., Tulliez, M., Giraudier, S., Guichard, J., Burstein, S. A., Cramer, E. M., Vainchenker, W., & Wendling, F. (1997) · Blood · doi:10.1182/blood.v90.11.4369 · Cited by 265
Epidemiology of myeloproliferative neoplasms in the United States
Mehta, J., Wang, H., Iqbal, S. U., & Mesa, R. (2014) · Leukemia & Lymphoma · doi:10.3109/10428194.2013.813500 · Cited by 247
Kramann, R., DiRocco, D. P., & Humphreys, B. D. (2013) · The Journal of Pathology · doi:10.1002/path.4253 · Cited by 211
Self-citationYan, X., Lacey, D., Hill, D., Chen, Y., Fletcher, F., Hawley, R., & McNiece, I. (1996) · Blood · doi:10.1182/blood.v88.2.402.bloodjournal882402 · Cited by 202
Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J. T., Popat, U., Alessandrino, E. P., Spivak, J. L., Smith, B. D., Klingemann, H. G., Fruchtman, S., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4299 · Cited by 199
CXC chemokine ligand 4 (Cxcl4) is a platelet‐derived mediator of experimental liver fibrosis†
Zaldivar, M. M., Pauels, K., von Hundelshausen, P., Berres, M., Schmitz, P., Bornemann, J., Kowalska, M. A., Gassler, N., Streetz, K. L., Weiskirchen, R., et al. (2010) · Hepatology · doi:10.1002/hep.23435 · Cited by 171
Kramann, R., Fleig, S. V., Schneider, R. K., Fabian, S. L., DiRocco, D. P., Maarouf, O., Wongboonsin, J., Ikeda, Y., Heckl, D., Chang, S. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74929 · Cited by 168
Self-citationSafar, V., Gastinne, T., Milpied, N., Maisonneuve, H., Morineau, N., Dubruille, V., Mahé, B., Moreau, P., Jardel, H., Planche, L., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2190.2190 · Cited by 168
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24592 · Cited by 163
Tefferi, A., Lasho, T. L., Tischer, A., Wassie, E. A., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2014) · Blood · doi:10.1182/blood-2014-07-588426 · Cited by 161
Aberger, F., & Altaba, A. R. I. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.05.003 · Cited by 151
Moshai, E. F., Wémeau-Stervinou, L., Cigna, N., Brayer, S., Marchal-Sommé, J., Crestani, B., & Mailleux, A. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0154oc · Cited by 96
Burstein, S. A., Malpass, T. W., Yee, E., Kadin, M. E., Brigden, M. L., Adamson, J. W., & Harker, L. A. (1984) · British Journal of Haematology · doi:10.1111/j.1365-2141.1984.tb02912.x · Cited by 73
Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
Sasaki, K., Gotlib, J. R., Mesa, R. A., Newberry, K. J., Ravandi, F., Cortes, J. E., Kelly, P., Kutok, J. L., Kantarjian, H. M., & Verstovšek, S. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.984703 · Cited by 61
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management
Tefferi, A. (2011) · American Journal of Hematology · doi:10.1002/ajh.22210 · Cited by 54
Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis
Bhagwat, N., Keller, M. D., Rampal, R. K., SHANK, K. R., de Stanchina, E., Rose, K. L., Amakye, D. D., & Levine, R. L. (2013) · Blood · doi:10.1182/blood.v122.21.666.666 · Cited by 54
Abraham, N. G., Feldman, E. J., Falck, J. R., et al. (1991) · Blood · doi:10.1182/blood.v78.6.1461.1461 · Cited by 46
JAK-Mutant Myeloproliferative Neoplasms
Levine, R. L. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_170 · Cited by 30
Thiele, J., KUEMMEL, T. A., Sander, C., & Fischer, R. (1991) · PubMed · Cited by 28
Pathogenesis of Myelofibrosis With Myeloid Metaplasia: Lessons From Mouse Models of the Disease
Vannucchi, A. M., Migliaccio, A. R., Paoletti, F., Chagraoui, H., & Wendling, F. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.04.008 · Cited by 17
Stromal cells in primary myelofibrosis: ultrastructural observations
Biagini, G., Severi, B., Govoni, E., PREDA, P., Pileri, S. A., Martinelli, G. N., Visani, G., Finelli, C., & Castaldini, C. (1985) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02890110 · Cited by 10
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Humphreys, B. D. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034227 · Cited by 1,231
Self-citationHaematopoietic stem cell activity and interactions with the niche
Pinho, S., & Frenette, P. S. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0103-9 · Cited by 984
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
Bone marrow niches in haematological malignancies
Méndez-Ferrer, S., Bonnet, D., Steensma, D. P., Hasserjian, R. P., Ghobrial, I. M., Gribben, J. G., Andreeff, M., & Krause, D. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0245-2 · Cited by 484
Metadata
- Authors
- Schneider, R. K., Mullally, A., Dugourd, A., Peisker, F., Hoogenboezem, R., Van Strien, P. M. H., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., Müller-Newen, G., Wongboonsin, J., Ventura Ferreira, M., Puelles, V. G., Saez-Rodriguez, J., Ebert, B. L., Humphreys, B. D., & Kramann, R.
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 20
- Issue
- 6
- Pages
- 785-800.e8
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W2607959672
- Cited by
- 272
- References
- 43
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.